




RealRate

PHARMACEUTICAL 2022

Pacira Biosciences Inc
Rank 316 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Pacira Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pacira Biosciences Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Pacira Biosciences Inc is the variable Liabilities, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 48% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	866,048
Cost of Goods Sold	140,255
Intangible Assets	769,143
Liabilities, Current	521,118
Liabilities, Non-Current	91,699
Other Assets	251,761
Other Compr. Net Income	-151
Other Expenses	70,888
Other Liabilities	732,128
Other Net Income	-33,520
Other Revenues	541,533
Property and Equipment	188,401
Research and Development	55,545
Selling, General and Administrative Expense	199,345

Output Variable	Value in 1000 USD
Assets	2,075,353
Liabilities	1,344,945
Expenses	466,033
Revenues	541,533
Stockholders Equity	730,408
Net Income	41,980
Comprehensive Net Income	41,904
BaseVar	2,230,768
ECR before Limited Liability	96%
Economic Capital Ratio	227%